CHMP recommends label extensions for Afinitor, Enbrel, Cayston and Humira
This article was originally published in Scrip
Executive Summary
The EMA's Committee for Medicinal Products for Human Use has recommended label extensions for four drugs: Novartis' Afinitor (everolimus), Gilead Sciences' Cayston (aztreonam), Pfizer's Enbrel (etanercept) and Abbott's Humira (adalimumab).